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 ABSTRACT                                                                                                                                            
Sickle cell anemia: Review and remedial hope
Dinesh Parmar
Department of Genetics, Barkatullah University, Bhopal, India
Genetic diseases and disabilities have been described as the most ubiquitous 
and burdensome to the populations. The hereditary anemia especially due to 
sickle cell is common globally with variably high prevalence in indigenous 
populations. In India, several endogamous tribal pockets that have been ma-
laria endemic harbor sickle cell gene in strikingly high frequency. In this back-
ground management of sickle cell patients in context of contemporary health 
care system remains limited and requires integration of appropriate strategies 
into the existing health care delivery system. This may involve research, di-
agnosis, training, genetic counseling and possible remedial interventions for 
urban as well as rural populations. Remedial interventions that are possible in 
existing health care delivery system and potential therapies under investigation 
have been discussed.
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Human adult hemoglobin consists of 
two components, Hb A and Hb A2. All 
the human hemoglobins have a similar 
overall structure with two distinct pairs 
of peptide chains, each related to a single 
haem unit. In Hb A, α-chains are paired 
with β-chains (α2 β2) and in Hb A2 with 
δ-chains (α2δ2). All seven types of poly-
peptide chains (α, β, Aγ Gγ, δ, Є and ζ ) 
combine to form the various hemoglo-
bins found during human development1. 
Intrinsic defects of the erythrocytes 
or hemoglobinopathies are inherited 
changes of hemoglobin molecule lead-
ing to metabolic disorders. They fall into 
two major groups, viz.
i. Diseases resulting from` an inherited 
structural alteration in one of the globin 
peptide chains and
ii. Those due to inherited defects in the 
rate of synthesis of the globin chains.
Sickle cell hemoglobin (Hb S) is the 
most common erythrocytic abnormality 
which belongs to the first group, having 
structural alteration at molecular level in 
β globin chain. A single base pair in the 
β globin gene is mutated from adenine 
to thymine, producing a corresponding 
change in the sixth amino acid of pro-
tein from glutamic acid to valine result-
ing in its altered structure2،3. Since early 
20th century very many reports appeared 
on prevalence of this disorder in various 
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pockets of the world populations thus, 
studies on sickle cell haemoglobin have 
been important for its high frequency 
in many indigenous populations of the 
world. 
Reports on genetics, physiological and 
molecular basis, clinical consequences 
as well as possible explanation of the 
existence of this molecular abnormal-
ity in high frequencies have also been 
advanced. It seems reasonable to recall 
these important investigation reports in 
light of the fact that previously report-
ed population groups which harbored 
sickle cell gene may still possess this 
abnormal gene in more or less same 
frequencies besides slow but continu-
ous alterations in population structure 
due to many dynamic factors, hence 
imposing serious health burden in con-
temporary world. 
Apart from this, in view of the vastness 
of the country and the multiracial na-
ture of the peoples of India, the infor-
mation is meager therefore; systematic 
indepth investigations are still required 
taking into account other important 
variables which may involve the ethnic 
origin, the social, environmental and 
nutritional aspects as well as prevalent 
diseases in various pockets of human 
populations. Moreover, simple diagno-
sis method and possible remedial in-
terventions in case of sickle cell crisis 
must be communicated to the medical 
professionals; especially those who are 
working in rural tribal areas where high 
prevalence of sickle cell anaemia has 
been found. 
Physiological Basis and Clinical Con-
sequences:
Clinically the sickle cell disease re-
sulting from homozygous state of Hb 
S gene has shown a wide spectrum of 
morbidity in different regions of the 
world. The disease appeared in severe 
form with mortality in childhood in 
West and North Africa. Various factors 
have been suggested to influence the 
morbidity and the disease crisis. V.E. 
Emmele (1927) suggested that disease 
crisis is primarily due to precipitation 
of Hb S resulting in sickle shape under 
deoxygenated condition4. J.G. Huck5, 
noted that sickling  was a reversible 
process5. V.P. Sydenstricker (1924) re-
ported additional findings, including 
the variability in the course of illness.6 
E.V. Hahn and E.B. Gillespie7 confirmed 
the intimate relationship between the 
sickling of red cell and a reduced sup-
ply of oxygen and also demonstrated 
that sicked red cells could revert to 
their normal shape when exposed to ad-
equate amount of oxygen. Significantly 
these two workers, as early as in 1927, 
also rightly attributed the defect in the 
sickling phenomenon to the hemoglo-
bin contained within the red cells and 
not to the red cell itself.7
Early major contributions by L.W. 
Diggs and R.E. Ching8 included the 
first detailed post-mortem reports on 
patients with sickle cell disease in the 
USA8. Five years later, L.W. Diggs 
and associate J. Bibb also reported on 
certain hematological parameters (hae-
moglobin content, red cell fragility and 
detailed morphology of sickled cells) in 
patients suffering from sickle cell ane-
mia9. They noted for the first time the 
presence of red cells which were irre-
versibly sickled even after adequate re-
oxygenation.
The period between 1940 and 1960 
witnessed rapid advances in the un-
derstanding of various facets of this 
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disease. T.H. Ham and N.B. Castle10, 
elaborated on the pathogenesis of the 
vicious cycle of sickling in vivo, that 
is sickling results in increased viscos-
ity of blood, which leads to reduced cir-
culation and increased deoxygenation, 
which in turn causes further sickling10. 
I. J. Sherman11 observed that deoxygen-
ated sickled cells exhibited optical bi-
refringence, a phenomenon which was 
not seen in normal red cells11. This was 
probably the first evidence that the de-
oxygenated form of sickle hemoglobin 
has an orderly structure. 
The cells sickle at the oxygen tension 
normally found in the venous blood. 
When the level of healthy red cells be-
comes too low, this can lead directly or 
indirectly to a variety of c`omplications 
which include hemolytic crisis and 
anaemia, jaundice, colelithiasis, aplas-
tic crisis, autosplenectomy, sequestra-
tion crisis, dactylitis, priapism and re-
nal papillary necrosis etc. Pulmonary 
hypertension, conjunctival and retinal 
vessel alterations have also been report-
ed in sickle cell disease12،13. The cells 
with increased rigidity move slowly 
or become jammed in capillaries, with 
resultant damming up of blood which 
eventually leads to infarction14. Overt 
and incomplete (silent) cerebral infarc-
tion has also been reported in selective 
cases of sickle cell anemia15. For sickle 
cell homozygotes, the mortality rate has 
been reported very high and nearly half 
die in the first year of life whereas, the 
majority of children who are carriers of 
sickle cell gene die during their first 10 
years of life from complications1. The 
crises may mimic acute rheumatism or 
an acute abdominal lesion. Incidences 
of osteomylitis and bilateral leg ulcers 
have been noted in nearly 40% pa-
tients.16 
Sickling phenomenon greatly depends 
on the amount of Hb S hence, The het-
erozygotes with 50% or below remain 
free from the clinical problem whereas, 
those with more than 50% as in SS, SC, 
S-Thalassaemia, SO, SE and SD (Arab) 
have normally greater risk of sickle cell 
crisis. Moreover, person with Hb S as 
well as HPFH enjoys an advantage due 
to persistent Hb F as an efficient oxygen 
carrier17. HPFH is a condition charac-
terized by the fetal hemoglobin in adult 
life in the absence of any marked he-
matological abnormality or apparent ill 
effect even in persons who are homo-
zygous for this mutation and have only 
Hb F.2
It has been interesting that a “switch” 
gene seems to be involved in the change 
from synthesis of γ chains (Hb F) in 
fetal life to the synthesis of β chains 
(Hb A) in postnatal life. The regulation 
by the “switch” gene must be at the lev-
el of the chromosome as evident by the 
fact that person heterozygous for the 
high-F gene has nearly half Hb F and 
half Hb A. Furthermore, the person het-
erozygous for both high-F gene and the 
sickle gene has no Hb A but shows no 
interference with Hb S synthesis. The 
homozygote for high-F not only exhib-
its absence of Hb A but also lack the 
minor component normally found in the 
adult, Hb A2 (α2δ2). The δ locus is close-
ly linked with the β locus representing 
a plausible model envisions an “opera-
tor” gene that controls the function of 
at least two structural genes, the β lo-
cus and the δ locus. In addition, other 
gene possibly like γ as well constitutes 
a unit called operon. It is suggested that 
there may be one or more regulator loci 
in other chromosomes that influence the 




The diagnosis is made by observing 
characteristic sickle cells in the periph-
eral blood. Normally, sickle cells are 
observed in the stained blood film used 
for routine microscopy only in homozy-
gotes. Heterozygotes do not show sick-
ling on the film unless reducing agent 
like sodium meta-bi-sulphite (2% solu-
tion) is added to the blood. This simple 
and rapid method of demonstrating 
sickling of red cells without stain, us-
ing reducing agent on microscopic slide 
has been earlier suggested18 and can be 
conveniently adopted for diagnosis by 
Primary Health Centers of rural areas. 
Sickle cell hetero - and homozygotes 
can be recognized by electrophore-
sis on cellulose acetate plates or other 
medium involving starch or paper con-
ventionally used for electrophoretic 
separation. Homozygotes demonstrate 
a single main band of Hb S whereas, 
heterozygotes show a mixture of Hb 
A and S2. Isoelectric focusing, cation 
exchange and high performance liquid 
chromatography (HPLC) are also being 
used for laboratory diagnosis of sickle 
cell anemia.19,20
Molecular techniques are generally em-
ployed for prenatal diagnosis of sickle 
cell anemia which involve simple strat-
egies based on amplifying the β globin 
gene using polymerase chain reaction 
(PCR), followed by restriction analy-
sis3. Beside this, microarray based hu-
man globin gene mutation detection 
methods are also available and may 
gradually substitute conventional meth-
ods to the extent that their widespread 
use reduces their cost, which at present 
is high21. Moreover, a family study is 
always of fundamental importance to 
establishing diagnosis.20
Transmission and Molecular Basis:
The transmission of the trait was shown 
by J.V. Neel22, to follow the simple 
Mendalian principle in which those se-
verely affected were homozygous for 
the mutant gene22. In this instance, the 
heterozygotes could also be recognized 
clinically by a mild form of the disease 
referred to as sickle cell trait. L. Paul-
ing and associates23, reported a chemi-
cal difference between the hemoglobin 
of sickle cell patients (Hb S) and that 
of normal individual (Hb A). The two 
types of molecules could be separated 
by electrophoresis which indicated a 
difference in the net charge on the two 
types of molecules23. The persons who 
were heterozygous were found to pos-
sess both molecular species in a ratio 
approaching one to one (60: 40), result-
ed due to presence of one gene for Hb A 
and one gene for Hb S. They are usually 
normal hematologically and clinically, 
although hematuria and splenic infarc-
tion can occur under anoxic conditions. 
Normal erythrocytes become sickled in 
the trait when oxygen saturation falls 
below 40%, a level which is rarely 
reached in venous blood.16
The work on hemoglobin was signifi-
cant because this was the first demon-
stration of an inherited change in the 
molecular structure of a protein. Since 
the change was inherited in simple 
Mendalian fashion, the alteration was 
thought to be due to a single muta-
tion. Although, one could not define 
the alteration with certainty, the work 
of Sanger on sequences of amino acids 
in insulin polypeptide chains indicated 
that the difference might be due to ami-
no acid substitution.
In spite of magnitude of the problem, 
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the alteration in hemoglobin S was 
demonstrated within a remarkably short 
time on the basis of experiments on 
digestion of haem-protein with tryp-
sin, which cleaved polypeptide chains 
on paper by a combination of chro-
matography and electrophoresis, V.A. 
Ingram24 demonstrated that the differ-
ence between hemoglobin A and S were 
due to the substitution of single amino 
acid. In haemoglobin A, glutamic acid, 
which has a free carboxyl group, had 
been replaced by the neutral residue of 
valine to form hemoglobin S.24
A few years later when V.M. Ingram and 
his colleague, J. A. hunt, examined an-
other mutant hemoglobin C, they found 
that it had a different substitution at the 
same site in the polypeptide chain. In 
this instance, the basic amino acid, ly-
sine was substituted for glutamic acid25. 
By this time hemoglobin had been 
shown to be composed of four peptide 
chains, two identical α- chains and two 
identical β- chains. Both substitutions 
mentioned were in the β- chains.
Infant or Pre-reproductive Mortal-
ity:
A.C. Allison26 had mentioned about the 
virtual lethality of homozygous sickle 
cell conditions in Africa26, whereas, H. 
Lehamann and R.G. Huntsman27 stated 
that in West Africa a number of sickle 
cell homozygotes survived to become 
adults and their number was greater 
amongst sophisticated regions of West 
Africa, particularly amongst the upper 
class27. In India, a few studies on hae-
moglobinopathies have also demon-
strated the survival of sickle cell homo-
zygotes to adulthood.28-31 
Apart from this, a clear declining trend 
of sickle cell trait in ascending age 
groups was noted in Bhilala, Barela and 
Korku tribes. This trend and some fam-
ily studies in these tribal groups strong-
ly suggested infant or pre-reproductive 
mortality. This has also shown the pos-
sible adverse effects of both homozy-
gotes and heterozygotes on the health of 
the tribals living in poor environmental 
conditions32. Recently, susceptibility 
of severe cases of sickle cell patients 
to chronic pain, strokes and premature 
death has been reported by CBS News, 
U.S.A. in background of the fact that 
nearly 7 million African Americans suf-
fer from sickle cell anemia.33
Origin of Sickle Cell Gene in India:
There has been much debate about 
the origin of sickle cell gene in India. 
Whether it is indigenous in origin or 
it had migrated from Africa to India 
in prehistoric times is not clear34-37. 
With the help of endonuclease restric-
tion enzymes, Y.W. Kan and A. M. 
Dozi38, showed that the association of 
sickle cell gene with 7.6 kb recognition 
site found among the Valmiki, Konda 
Reddy and Koya Dora tribes in south-
ern India (probably Andhra Pradesh) is 
different from its association with 13.0 
kb recognition site among the people of 
western Africa38. They were in favor of 
view that the Indian and West African 
sickle gene mutations arose by separate 
events. Afterwards no attempts were 
made to further studies on origin of 
sickle cell gene by advanced molecular 
biology techniques.
Malaria-Sickle Cell Hypothesis: Pos-
sible Explanation of the Existence of 
Sickle Cell Gene:
Malaria is an acute infectious disease 
caused by malarial parasites, Plasmo-
dium vivax or Plasmodium falciparum, 
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transmitted by mosquitoes of the genus 
Anopheles. This illness is characterized 
by a cycle course with periods of acute 
febrile attacks and paroxysm free inter-
vals as well as by splenohepatomegaly, 
anemia and occasional severe lesions 
of the nervous system, kidneys and 
other organs. Relapses are also com-
mon. Even today this is one of the most 
wide-spread transmissible diseases in 
the world, with the African continent 
being the largest malaria stronghold on 
the globe. Furthermore, the disease is 
also rather wide spread in a number of 
countries of South-East Asia and South 
America.
Transmission of malaria is possible 
when a combination of several fac-
tors is available, including sources of 
infection, vectors, susceptible popula-
tion and favorable natural and climatic 
conditions. The source of infection is 
a malaria patient or parasite carrier 
whose peripheral blood contains ma-
ture sexual forms of malarial plasmo-
dia (gametocytes). In vivax, quartan 
and oval malaria, gametocytes appear 
in the blood in the first days of the dis-
ease, their number growing after a few 
attacks. In falciparum malaria, gameto-
phytes are discovered in the peripheral 
blood on the 8th-10th day from the onset 
of disease reaching the peak values by 
the 14th -15th day.39،40
In highly endemic malarial areas where 
the adult population possesses the ac-
quired immunity, children present the 
major source of malaria. Children do 
not have acquired immunity, hence 
their parasitaemia is usually heavy, 
the disease course is rather frequently 
atypical and the disease diagnosis is 
late41. Parasite carriers in endemic areas 
may serve as sources of infection for a 
long time because malaria in such indi-
viduals is rarely identified and they re-
ceive no treatment. Yet, the infectivity 
of gametocytes in immune individuals 
appears to be less marked than in non-
immune children.
A mosquito female of the genus Anoph-
eles serves as a host for the sexual cycle 
of parasite development, sporogony 
which may be complete only at a tem-
perature higher than 16ºC. At higher 
temperatures, the process of sporog-
ony accelerates. In conditions of hot 
climate, blood digestion by mosquito 
females occurs faster, they more of-
ten feed on humans and produce more 
oocytes which accounts for the higher 
intensity of infestation of the vector by 
sporozoites.
The sickle cell homozygotes apparently 
suffer from severe anemia and die be-
fore attaining reproductive age without 
contributing to the gene pool of the 
population. Therefore, observation of 
very high frequencies of sickle cell trait 
in various pockets of world populations 
called for an explanation. A number of 
considerations were advanced to ex-
plain the high frequencies of a delete-
rious gene like sickle cell27. The most 
acceptable possibility was the mecha-
nism of balanced polymorphism as was 
suggested by J.B.S. Haldane (1949) in 
connection with thalassaemia42 and lat-
er developed by A.C. Allison26 in popu-
lations with high incidence of sickling 
in Africa.43,44
A.C. Allison26 put forward the malaria-
sickle cell hypothesis which states that 
in the presence of Plasmodium falci-
parum malaria, the heterozygote sickle 
cell trait carriers enjoy a selective ad-
vantage over the normal homozygotes 
as the former are resistant to this par-
ticular type of malaria43. It has been 
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suggested that Hb S offers protection 
against P. falciparum probably because 
of deoxy-Hb S aggregates with RBC 
interfering with intra-erythrocytic schi-
zogony and their subsequent removal 
by macrophages. This selective advan-
tage has given rise to balanced poly-
morphism in relation to the Hb S and is 
mainly responsible for maintenance of 
high frequencies of sickle cell gene in 
malaria endemic regions of Africa.
Though the malaria-sickle cell hypoth-
esis appeared to be the best plausible 
explanation of the high frequencies of 
sickle cell trait yet, some objections to 
the validity of the hypothesis became 
evident when hypothesis was examined 
in relation to the distribution of sickle 
cell trait in some population groups of 
India45،46. In India, the first report on 
the role of selective advantage of sickle 
cell gene was published in 1974 among 
Mahars of Aurangabad where a good 
correlation between the endemicity of 
malaria and the incidence of Hb S trait 
was observed47. In another study on 
Bhilala and Barela tribes of West Nimar 
and Korku tribe of Pachmarhi hills of 
Central India, significant correlation in 
the distribution of sickle cell trait and 
incidence of malaria has been noted.32 
Distribution of Sickle Cell Gene with 
Special Reference to India:
J.B. Herrick (1910), first recognized the 
presence of red cell which was shaped 
like a sickle in an anemic, West Indian 
medical student and it was considered 
to be a Negroid character48. However, it 
is now well established that this partic-
ular gene is widely distributed in other 
parts of the world including India with 
its highest incidence among black Afri-
cans and descendants of those who em-
igrated from equatorial Africa. It was 
earlier reported that nearly 8% of black 
population in the United States49-51, 
Latin America and Caribbean52&53 carry 
sickle cell gene. Incidences were first 
reported in India from Nilgiri hills, 
South India34 and from Assam simulta-
neously28. Since then large data on the 
incidence of sickle cell gene have been 
collected in different tribal populations 
from Indian subcontinent.54
The frequency of Hb S ranging from 
0.5% among Tadas of Nilgiri hills in 
Tamil Nadu to 34.43% among Pani-
yans has been reported from southern 
India34,55&56. The frequency of Hb S in 
western India ranges from 0.02% to 
30.6%. The highest frequency at 30.6% 
has been reported among Sorathis and 
the lowest at 0.02% among Parsis of 
Gujarat57&58. Some hospital cases of Hb 
S associated with thalassemia had been 
reported from Maharashtra.59&60 
In eastern India, frequency of Hb S 
has been reported from 1.7% among 
Santhal tribe of West Bengal to 29% 
among Griza Oriahans of Assam61&62. 
Non-tribals of Assam however, rare-
ly show a frequency of Hb S more 
than 10% particularly among upper 
castes57,63-68. Frequency of sickling 
ranged from 1.4% among the un-
known community of Mirzapur, in Ut-
tar Pradesh to 23.64% among Garasia 
of Sirohi in Rajasthan in northern In-
dia.69,70
Many tribal groups of central India 
have been reported to possess Hb S in 
considerably high frequencies. In Ba-
star and Bilaspur districts, frequencies 
of Hb S ranging from 3.45% among 
Dhurva to as high as 48.58% among 
Panka (mixed) have been reported45. 
A few surveys have however, shown 
complete absence of sickle cell trait in a 
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number of tribal groups of India which 
include few tribes of central region in-
volving Dhanwar, Manjhwar, Oraon, 
Kol and Pando and Kanwar.64،70-74,37  
Bhils in central region have shown 
variations in frequency of Hb S rang-
ing from 5.90% to 23.91%75&76. A com-
paratively high frequency has been 
reported among Bhilala ranging from 
9.51% to 28.50% in different pockets 
of their population77,78,32. Among Pate-
lia of the same region, the frequency of 
Hb S ranged from 20.48% to 31.10%77. 
Frequency of Hb S ranging from 14. 
68% to 24.64% was observed among 
Barela in Khargone of this region32,78. A 
tribe Pardhan of Mandla district was re-
ported to harbor 9.0% Hb S79. Korku of 
Pachmarrhi hills in Hoshangabad dis-
trict were found to have considerably 
high frequency of Hb S being 16.86%32.
Whereas, in neighboring Chindwara 
district in central India, Korku and 
Bharia tribes exhibited comparatively 
lower frequencies of Hb S, 7.20% and 
2.60%, respectively80. Gond, Halba 
and Kawar tribes of Raipur have also 
been investigated for Hb S. These tribes 
have shown the frequencies of sickle 
cell trait to be 15.92%, 13.90% and 
5.50%, respectively77. Hence, persis-
tence of sickle cell gene in considerably 
high frequencies in various indigenous 
population groups of India remains a 
serious health burden in background of 
their poor environmental and economic 
status.
Remedial Hope for Sickle Cell Pa-
tients:
Management of sickle cell patients in 
context of existing contemporary health 
care system is limited and requires inte-
gration of appropriate strategies into the 
existing health care delivery system. 
Management strategies may involve de-
velopment of research, diagnosis, train-
ing, genetic counseling and possible re-
medial interventions in such a way that 
both urban as well as rural populations 
are benefited. Strategy for prevention 
and possible remedial interventions as 
suggested by H.M. Bhatia62 is consider-
able in case of sickle cell crisis17. This 
involves following points:
1. Rapid diagnosis and avoidance of 
unnecessary surgical intervention.
2. Prevention of infarcts and forma-
tion of thrombi in circulatory sys-
tem.
3. Avoid vascular stasis.
4. Avoid cold and cold bath or drink-
ing cold water.
5. Avoid excessive heat to prevent de-
hydration.
6. Give magnesium sulphate injec-
tion during crisis. It helps in clot-
ting process, delays thrombi forma-
tion and acts as vasodilatory agent 
in dislodging nests of sickle cells 
from small venules.
7. Avoid intravascular sickling, pH is 
kept alkaline with oral administra-
tion of sodium bicarbonate, 2-3 gm 
per day in divided doses as a pre-
caution to prevent crisis especially 
during infections.
8. Avoid infections as well as malaria.
9. Provide adequate fluid intake to 
avoid dehydration.
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10. Prophylactic antibiotics and anti-
malarial drugs are useful in pre-
venting crisis.
11. Selection of these drugs should take 
note of the G6PD deficiency.
12. Provide folic acid supplements 
without iron supplements. Iron sup-
plement should follow the serum 
iron estimation.
13. Maintain haemoglobin level be-
tween 6-9 gm per cent.
14. Give transfusion only if haemoglo-
bin level falls to or below 5.0 gm 
per cent.
15. Avoid protracted labor or caesarean 
operation.
16. Leg ulcers may be resistant to treat-
ment. Keep under warm stockings 
in cold weather and give conserva-
tive treatment to avoid infections.
Moreover, these days some promising 
therapies for sickle cell anemia are be-
ing investigated through research which 
involve the following methods:
1. One method for treating sickle cell 
anemia is to reduce the concentra-
tion of defective hemoglobin by 
stimulating the body to make other 
kinds of hemoglobin. Hydroxyurea 
(Droxia), a cancer medication, has 
been shown to reduce pain and 
complications in sickle cell anemia 
in adults. It is still being investigat-
ed for use in children, with special 
concern for how hydroxyurea may 
affect child growth and develop-
ment81. Two other drugs being in-
vestigated to stimulate hemoglo-
bin production are butyrate and 
arginine. Studies have shown both 
drugs not only increase healthy he-
moglobin but also reduce the symp-
toms of sickle cell anemia as well.82
2. Since the pain of sickle cell ane-
mia comes from blood vessels be-
ing blocked off, another method 
of treatment would be to get more 
oxygen to the painful areas. Polox-
amer 188 (Flocor), made by CytRx 
Corp., has been shown in studies 
to decrease the length of painful 
episodes in sickle cell anemia by 
improving blood flow in the tiny 
blood vessels around the painful 
area. In June 2001 the U.S. Food 
and Drug Administration (FDA) 
granted CytRx permission to put 
Flocor on the fast track for develop-
ment, for treatment of acute chest 
syndrome.83
3. Sickled red blood cells could also 
be made less “sticky” and thus less 
likely to block off blood vessels. 
A study published in 2001 showed 
that the drug sulphasalazine could 
reduce the number of “sticky” mol-
ecules on red blood cells in sickle 
cell anemia.84
Apart from this, cord blood transplant 
as a permanent remedy for sickle cell 
patient has recently made a medical 
history. Cord blood contains stem cells, 
the building blocks of the body’s blood-
making system. Cord blood is extracted 
from the umbilical cord and placenta at 
child birth. Cord blood transplants are 
especially promising for treating blood 
diseases like severe anemia or leuke-
mia because it is easier to match the 
immature cord stem cells of donors to 
unrelated patients whereas, finding two 
unrelated people with matching bone 
marrow cells remains extremely dif-
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ficult. A half, full or partially matched 
unit can in many cases take hold and 
form a new normal blood cell forming 
tissue after transplants.
Keone Penn, a 12 year old sickle cell 
patient in US in 2006 became the first 
child to receive a cord blood transplant 
as reported by CBS News Correspon-
dent R. Pinkston33. New transplanted 
blood-making system needs time to take 
root but by the time report appeared he 
had shown no sigh of sickle cell anae-
mia since the transplant was performed. 
It is encouraging that his cure may be-
come viable dream for other people 
with sickle cell anaemia in near future.
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